Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBITDA (2016 - 2025)

Regenxbio (RGNX) has 12 years of EBITDA data on record, last reported at -$67.2 million in Q4 2025.

  • For Q4 2025, EBITDA fell 30.85% year-over-year to -$67.2 million; the TTM value through Dec 2025 reached -$193.8 million, up 13.24%, while the annual FY2025 figure was -$193.8 million, 13.24% up from the prior year.
  • EBITDA reached -$67.2 million in Q4 2025 per RGNX's latest filing, down from -$61.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $292.7 million in Q4 2021 and bottomed at -$86.1 million in Q1 2022.
  • Average EBITDA over 5 years is -$41.9 million, with a median of -$59.5 million recorded in 2023.
  • The widest YoY moves for EBITDA: up 724.66% in 2021, down 803.7% in 2021.
  • A 5-year view of EBITDA shows it stood at $292.7 million in 2021, then tumbled by 119.5% to -$57.1 million in 2022, then dropped by 4.95% to -$59.9 million in 2023, then grew by 14.29% to -$51.3 million in 2024, then tumbled by 30.85% to -$67.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$67.2 million in Q4 2025, -$61.8 million in Q3 2025, and -$70.9 million in Q2 2025.